Andrew Caster, MD
Ophthalmology · Beverly Hills, CANPI 1821133067
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Rxsight Inc at 51.7% of the total. Reporting peaked in 2024 at $2,345 and has fallen 90.0% since, to $234 in 2025.
Across 44 payments — averaging $104.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$2K
- Carl Zeiss Meditec, Inc.$1K
- Optos, Inc.$239
- Novartis$139
- Sun Pharmaceutical Industries Inc.$125
- Dompe US, Inc.$119
- plus $358 from 10 others
What the payments were for
- Consulting fees$1,66636%
- Food & beverage$1,68336%
- Education$1,25027%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 9 | $2,387 |
| Carl Zeiss Meditec, Inc. | 1 | $1,250 |
| Optos, Inc. | 2 | $239 |
| Novartis | 6 | $139 |
| Sun Pharmaceutical Industries Inc. | 5 | $125 |
| Dompe US, Inc. | 4 | $119 |
| Carl Zeiss Meditec USA, Inc. | 2 | $62 |
| AbbVie(2 entities) | 3 | $59 |
| Oyster Point Pharma, Inc. | 3 | $58 |
| Alcon | 2 | $43 |
| Harrow Eye, LLC | 2 | $40 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Amgen | 1 | $18 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$2,116
- RXSIGHT INJECTOR CARTRIDGE$2,116
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,116
- LIGHT ADJUSTABLE LENS (LAL)$2,116
- RXSIGHT INJECTOR HANDPIECE$2,116
- VisuMax$1,250
- PANORAMIC OPHTHALMOSCOPE$420
- OCT OPHTHALMOSCOPE$210
- NFC-700$210
How this compares
$4,618 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 12 | $122 |
| Montelukast Sodium | 12 | $121 |
| Escitalopram Oxalate | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Beverly Hills
- Raymond DouglasBeverly Hills$1.3M
- Stuart StollBeverly Hills$673K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.